A leading investment expert forecasts a stronger year ahead for CSL shares. Let’s see why. The post 3 reasons to buy CSL ...

The offering is one of four biotech IPOs that could price by Friday, and comes during the busiest week for such activity ...

Mainland China's issuers will still dominate city's IPO market, executive says, but US and Southeast Asian companies are also ...

DelveInsight's Oncolytic Virus Competitive Landscape 2026 report provides comprehensive global coverage of pipeline oncolytic ...

ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer’s disease (AD) and other neurodegenerative disorders, today announce ...

ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer's disease ...

J&K Ingredients has entered a partnership with Pallas Biotech Co. Ltd., a global biotechnology company, that brings together complementary capabilities across research and development, fermentation, ...

When Impossible Foods announced that CEO Peter McGuiness would step down after nearly four years, the company framed the move as a transition “from a position of strength.” For Rachel Konrad, the ...

The three-venue concept will span two floors and 13,000 square feet. Partners include the team behind Cafe Weekend.

The FDA has granted fast track designation to the investigational oncolytic virus immunotherapy pelareorep (Reolysin) in combination with bevacizumab (Avastin) and FOLFIRI (leucovorin, fluorouracil, ...

Why is Sobi paying $950M upfront for Arthrosi? Analyze the deal terms, the $550M in milestones, and the projected growth through the 2030s.

Next, let’s go back to the second-best performer in the S&P for January, and that’s Moderna. That was up nearly 50%, and this was… a wild ride.